D. Valcárcel

发表论文 33 篇 · 总被引 157 次 · h-index 4

代表论文

• Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial (2025 · Advances in Therapy · 被引 6)
• Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial. (2025 · Journal of Clinical Oncology · 被引 5)
• Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study (2026 · Haematologica · 被引 2)
• Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS (2025 · Blood Cancer Journal · 被引 2)
• MDS-730: Overall Survival (OS) and Duration of Red Blood Cell-Transfusion Independence (RBC-TI) for First-Line Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept (LUSPA) vs Epoetin Alfa (EA) in the COMMANDS Trial (2025 · Clinical Lymphoma, Myeloma & Leukemia · 被引 2)
• Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes (2026 · Blood Cancer Journal · 被引 1)